Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jaguar Animal Health ( (JAGX) ) has shared an update.
Jaguar Health, Inc. reported that as of December 31, 2025, it had a stockholders’ deficit of approximately $18.7 million, which left the company out of compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5 million in stockholders’ equity. However, by April 7, 2026, after receiving multiple capital inflows and recording a gain on extinguishment of certain debt, the company believes its stockholders’ equity exceeded the $2.5 million threshold. These cash proceeds and balance sheet improvements stemmed from a January 12, 2026 license agreement, a related supply agreement, product inventory purchases, Mytesi product sales, grant revenue, and a $3.4 million gain on partial debt extinguishment, which collectively strengthened Jaguar’s financial position and supported its ongoing Nasdaq listing compliance.
The most recent analyst rating on (JAGX) stock is a Sell with a $0.37 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
The score is driven mainly by weak financial health (large ongoing losses and negative equity) and bearish technicals (below key moving averages with negative MACD). Corporate events are mixed—liquidity-positive restructuring/licensing helps, but elevated Nasdaq delisting risk meaningfully offsets those positives; valuation support is limited due to losses and no dividend.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a pharmaceutical company focused on developing and commercializing prescription products, including through its wholly owned subsidiary Napo Pharmaceuticals, Inc. The company’s portfolio includes Mytesi, and it operates through licensing, manufacturing, and supply agreements with partners such as Woodward Specialty LLC and Future Pak, LLC to support product distribution and revenue generation.
Average Trading Volume: 3,933,464
Technical Sentiment Signal: Sell
Current Market Cap: $4.96M
For detailed information about JAGX stock, go to TipRanks’ Stock Analysis page.